# Phase 7.5 Risk-Floor Gate — LL-37

## Verdict

verdict: PASS

Compound risk_tier = experimental → BLOCKING floor applies (health-gates.md §2).
All four required Risk-Profile fields are present and cited; the experimental-tier
third-party objective monitoring marker requirement is satisfied (hs-CRP / ESR are
named objective lab assays). No halt reasons.

## Field-by-field (each: present? cited? location)

### adverse_effects_literature — populated (present: yes; cited: yes)
- Location: §9.1 (human-trial AE) + §9.2 (preclinical cytotoxicity/hemolysis).
- Preclinical: native LL-37 induces hemolysis and is toxic to human leukocytes/
  T-lymphocytes via membrane interaction [71]; concentration-dependent platelet
  toxicity (1–50 µM none, 100 µM significantly toxic) [72]; cytotoxic to many
  human cell types at ~1–10 µM, ~300 µM in psoriatic lesions [73].
- Human-trial AE: Grönberg 2014 "no safety concerns / safe and well tolerated"
  (existence-of-safety, not a rate) [28]; Phase IIb HEAL 12 non-fatal SAEs in 11
  patients (7.4%), none drug-related, explicitly framed as a BACKGROUND elderly-
  population rate, not a drug-attributable AE rate [29]; Dolkar 2018 n=1
  intratumoral-melanoma cutaneous toxicity case report [33].
- Honest no-data caveat present: "no quantified drug-attributable AE rate exists";
  "no human safety dataset for chronic use" implied throughout (§6.4, §9.5) — thin
  human safety dataset stated explicitly.

### contraindications — populated (present: yes; cited: yes)
- Location: §9.4 "Contraindications / caution" (and §9.3 mechanistic basis).
- Psoriasis / psoriatic arthritis / known LL-37 autoreactivity — LL-37 is the
  psoriasis T-cell AUTOANTIGEN + type-I-IFN innate trigger → mechanistically
  contraindicated / flare-risk [74][75].
- Other type-I-IFN / autoimmune conditions (SLE, RA) — caution [75].
- Active or history of malignancy (melanoma / skin SCC / breast / lung / ovarian /
  prostate / pancreatic) — context-dependent PRO-TUMOR signal [77][67].
- Pro-thrombotic states / antiplatelet considerations [72].
- High local concentration — concentration-dependent hemolysis/cytotoxicity above
  ~50–100 µM; efficacy lost at top topical dose 3.2 mg/mL [28][72][71].

### monitoring — populated (present: yes; cited: yes)
- Location: §9.4 "Objective monitoring (named assays)".
- Named objective assays: hs-CRP [[biomarkers/hs-crp]] and inflammatory cytokines
  (IL-6, TNF-α; IFN-α surrogate where available) [75]; CBC / platelet-function +
  bleeding-time/thrombotic vigilance [72]; skin examination for psoriasiform
  eruptions [33][74]; renal markers (creatinine) [29].
- Honest caveat present and explicit: these are general objective inflammation
  markers, NOT validated surrogates of LL-37 activity — "no LL-37-specific
  validated biomarker of effect exists."

### stopping_criteria — placeholder-with-pointer (present: yes)
- Location: §9.4 "Stopping rules" + §11 N=1 design + frontmatter
  doctor_discussion_required: true.
- Concrete inferred rules present: discontinue on new/worsening psoriasiform or
  inflammatory dermatologic reaction [33]; discontinue at concentrations producing
  local irritation (severe local reactions ≤3.4%/visit at trial doses) [29].
- Per health-gates §2 override, operator-specific stopping criteria for a library-
  canonical (operator-agnostic) entry are correctly carried as a present pointer to
  per-trial population (§11 + clinician involvement); section + pointer present.

### third_party_monitoring_marker_present — TRUE
- hs-CRP and ESR are NAMED OBJECTIVE LAB ASSAYS (third-party, not self-reported).
- Satisfies health-gates.md §2 special case: ≥1 monitoring item references
  [[biomarkers/<name>]] ([[biomarkers/hs-crp]]) or a named lab assay (hs-CRP, ESR).
- Honest caveat acknowledged: these are objective inflammation markers, not
  compound-specific validated surrogates — which the rule permits (a named
  objective assay need not be compound-specific).

## Structured verdict

```json
{"phase":"7.5","verdict":"PASS","timestamp":"2026-06-20T15:16:34Z","iterations":2,"compound_risk_tier":"experimental","compound_entry_path":"vault/library/peptides/ll-37/research-report.md","required_fields":{"adverse_effects_literature":"populated","contraindications":"populated","monitoring":"populated","stopping_criteria":"placeholder-with-pointer"},"third_party_monitoring_marker_present":true,"third_party_markers":["hs-CRP","ESR"],"halt_reasons":[],"attestation_chain":{"iter_start_ts":"2026-06-20T15:10:00Z","attest_ts":"2026-06-20T15:16:34Z","iteration":2,"agent_source_path":".claude/skills/aplus-research/references/health-gates.md","agent_source_sha256":"f15a70870b67eb498e3d380e478b83eb5f0de0a5fb04d864adf9104f0f36067e","agent_source_mtime":"2026-06-18T15:52:31Z"}}
```
